[1] BRYANT ML，BRIDGES EG，PLACIDI L，et al. Antiviral L-nucleosides specific for hepatitis B virus infection[J]. Antimicrob Agents Chemother，2001，45：229.
[2] ZHOU XJ，LIM SC，LLOYD DM，et al. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharrnacodynamic implications[J]. Antimicrob Agents Chemother，2006，50：874.
[3] ZHOU XJ，FIELMAN BA，LLOYD DM，et al. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil[J]. Antimicrob Agents Chemother，2006，50：2309.
[4] 中华医学会传染病与寄生虫病学分会、肝病学分会. 病毒性肝炎防治方案[J]. 中华传染病杂志，2001，19（1）：56-62.
[5] 中华医学会肝病学分会、感染病学分会. 慢性乙型肝炎防治指南[J]. 实用肝脏病杂志，2006，9（1）：8-18.
[6] LOK AS. Navigating the maze of hepatitis B treatments[J]. Gastroenterology，2007，132:1586-1594.
[7] LAI CL，LEUNG N，TEO EK，et al. A 1-year trial of telbivudine，lamivudine，and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B[J]. Gastroenterology，2005，129:528.
[8] 贾继东，侯金林，尹有宽，等. 替比夫定或拉米夫定抗乙型肝炎病毒的疗效预测探讨[J]. 中华肝脏病杂志，2007，15（3）：342-345.
[9] HOU J，YIN YK，XU D，et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B:Results at 1 year of a randomized，double-blind trial[J]. Hepatology，2008，47:447-454. |
